IR Notice
Dear Shareholders,
Stable Manufacturing and Business OperationsSamsung Biologics announced our 2020 Q3 Earnings today. Despite the ongoing COVID-19 pandemic, we maintained stable business operations including development and manufacturing according to our strict COVID-19 controls and management system.
- 2020 Q3
-
- Revenue
- 2,746B KRW(QoQ 11% DOWN, YoY 49% UP)
- Operating Profit
- 565B KRW (QoQ 30% DOWN, YoY 139% UP)
- Profit Before Incom Tax
- 737B KRW (QoQ 9% UP, YoY 67% UP)
- Net Profit
- 561B KRW (QoQ 8% UP, YoY 27% UP)
- Manufacturing Contracts and Business Performance
-
- 4 additional contracts in Q3 11 cumulative contracts in 2020 thus far
- plant 4 Expansion(august)
- S-CHOiceTMLaunched(August)
Continuing to Strengthen Business Competitiveness Towards Becoming a Super Value Company
In August, we announced our Plant 4 expansion, which will have a capacity of 256,000L. With the Plant 4 expansion Samsung Biologics is proactively responding to changes in the global biopharmaceutical market and is strongly positioned as the global No.1 CMO based on production capacity. applying Super Value Company principles in the CDO(contract development)market, we continue to strengthen our competitive edge. Samsung Biologics successfully launched our own cell line, S-CHOiceTM, in August 2020. The S-CHOiceTM cell line results in shorter production times and price competitiveness for our clients. Additionally, to strengthen client satisfaction and bring our contract development services closer to global clients, we are launching a CDO R&D Center in San Francisco, California on October 29th(KST). I encourage you to attend the online grand opening ceremony of our CDO R&D Center. Please register through the link at the bottom of the letter. Samsung Biologics will contnue to innovate to provide qualiy services for clients to support them in their mission to advance life-saving therapies. Thank you, Tae Han Kim President & CEO, Samsung Biologics October 21, 2020
뿐만 아니라 글로벌 거점과 고객사 확보 역량 강화를 위해 10월 29일 미국 San Francisco에 CDO R&D 센터를 오픈할 계획입니다. 온라인으로 진행되는 본 행사에 관심 있으신 투자자분들은 메일 하단의 '등록'을 통해 참석하실 수 있습니다. 삼성바이오로직스는 앞으로도 지속적인 혁신을 통해 빠른 속도로 양질의 서비스를 제공하며, 보다 높은 기업가치 창출을 위해 최선을 다하겠습니다. Super Value Company를 향한 삼성바이오로직스의 행보에 투자자 여러분들의 따뜻한 관심과 지속적인 성원을 부탁드립니다. 감사합니다. 2020년10월21일 삼성바이오로직스 대표이사 사장 김태한
Dear Shareholders,
Stable Manufacturing and Business OperationsSamsung Biologics announced our 2020 Q3 Earnings today. Despite the ongoing COVID-19 pandemic, we maintained stable business operations including development and manufacturing according to our strict COVID-19 controls and management system.
- 2020 Q3
-
- Revenue
- 2,746B KRW(QoQ 11% DOWN, YoY 49% UP)
- Operating Profit
- 565B KRW (QoQ 30% DOWN, YoY 139% UP)
- Profit Before Incom Tax
- 737B KRW (QoQ 9% UP, YoY 67% UP)
- Net Profit
- 561B KRW (QoQ 8% UP, YoY 27% UP)
- Manufacturing Contracts and Business Performance
-
- 4 additional contracts in Q3 11 cumulative contracts in 2020 thus far
- plant 4 Expansion(august)
- S-CHOiceTMLaunched(August)
Continuing to Strengthen Business Competitiveness Towards Becoming a Super Value Company
In August, we announced our Plant 4 expansion, which will have a capacity of 256,000L. With the Plant 4 expansion Samsung Biologics is proactively responding to changes in the global biopharmaceutical market and is strongly positioned as the global No.1 CMO based on production capacity. applying Super Value Company principles in the CDO(contract development)market, we continue to strengthen our competitive edge. Samsung Biologics successfully launched our own cell line, S-CHOiceTM, in August 2020. The S-CHOiceTM cell line results in shorter production times and price competitiveness for our clients. Additionally, to strengthen client satisfaction and bring our contract development services closer to global clients, we are launching a CDO R&D Center in San Francisco, California on October 29th(KST). I encourage you to attend the online grand opening ceremony of our CDO R&D Center. Please register through the link at the bottom of the letter. Samsung Biologics will contnue to innovate to provide qualiy services for clients to support them in their mission to advance life-saving therapies. Thank you, Tae Han Kim President & CEO, Samsung Biologics October 21, 2020
뿐만 아니라 글로벌 거점과 고객사 확보 역량 강화를 위해 10월 29일 미국 San Francisco에 CDO R&D 센터를 오픈할 계획입니다. 온라인으로 진행되는 본 행사에 관심 있으신 투자자분들은 메일 하단의 '등록'을 통해 참석하실 수 있습니다. 삼성바이오로직스는 앞으로도 지속적인 혁신을 통해 빠른 속도로 양질의 서비스를 제공하며, 보다 높은 기업가치 창출을 위해 최선을 다하겠습니다. Super Value Company를 향한 삼성바이오로직스의 행보에 투자자 여러분들의 따뜻한 관심과 지속적인 성원을 부탁드립니다. 감사합니다. 2020년10월21일 삼성바이오로직스 대표이사 사장 김태한